Vital Therapies Seeks $86.52M In IPO

San Diego-based Vital Therapies has filed for an IPO, saying in a filing late Friday that it is looking to raised $86.25M in an IPO effort on the NASDAQ Global Market. The company is looking to trade as VTL. The company, which develops cell-based treatments for acute liver failure, is backed by private investors, including Wall Street financier Muneer A. Satter, who owns 48.6 percent of the company. The company's IPO is being underwritten by Credit Suisse, William Blair, Cowen and Company, and Canaccord Genuity.